Table 2.
CMR results
| All n = 80 | Male n = 45 | Female n = 35 | |
|---|---|---|---|
| LV ejection fraction, % (range) |
58 (38–73) |
57 (45–73) |
61 (38–71) |
| LV systolic dysfunction, n (%) |
20 (25%) |
16 (36%) |
4 (11%) |
| LV enddiastolic volume, ml/m2 (range) |
72 (38–117) |
77 (41–117) |
67 (38–104) |
| LV endsystolic volume, ml/m2 (range) |
31 (11–63) |
35 (14–63) |
28 (11–56) |
| LV dilatation, n (%) |
7 (9%) |
6 (13%) |
1 (3%) |
| LV mass, g/m2 (range) |
47(30–79) |
50 (36–79) |
41(30–67) |
| LV wall hypertrophy, n (%) |
6 (8%) |
4 (9%) |
2 (6%) |
| RV ejection fraction, % (range) |
64 (38–77) |
60 (38–77) |
67 (50–76) |
| RV systolic dysfunction, n (%) |
4 (5%) |
4 (9%) |
0 |
| RV enddiastolic volume, ml/m2 (range) |
66 (40–117) |
71 (40–117) |
61 (40–102) |
| RV endsystolic volume, ml/m2 (range) |
23 (10–66) |
28 (10–66) |
20 (10–46) |
| RV dilatation, n (%) |
1 (1%) |
1 (2%) |
0 |
| RV outflow tract, mm (range) |
26 (21–37) |
27 (22–37) |
25 (21–29) |
| Myocardial fibrosis, n (%) | 10 (13%) | 7 (16%) | 3 (9%) |